Regulation of Stemness by NR1D2 in Colorectal Cancer

Area of Science:

• Oncology
• Molecular Biology
• Chronobiology

Background:

• Nuclear Receptor Subfamily 1 Group D Member 2 (NR1D2) is a circadian clock regulator implicated as an oncogene in colorectal cancer (CRC).
• NR1D2's role in regulating cancer stem cells (CSCs) and relapse in CRC remains understudied.
• The tumor suppressor p53, mutated in ~50% of CRCs, is a key link between circadian clock disruption and cancer, and regulates CSC phenotypes.

Purpose of the Study:

• To investigate the role of NR1D2 in colorectal cancer stemness.
• To determine the influence of p53 status on NR1D2's effect on cancer stem cells.
• To analyze NR1D2 expression in CRC patient tumors and correlate it with clinical characteristics.

Main Methods:

• Developed an in vitro model using isogenic CRC cell lines with varying p53 functional status and silenced NR1D2.
• Analyzed NR1D2 expression in a patient cohort.
• Correlated NR1D2 expression with tumor differentiation and CSC marker expression.

Main Results:

• NR1D2 silencing reduced cell growth and stemness in cells with wild-type p53.
• Conversely, NR1D2 knockout increased cell growth and stemness in cells with non-functional or mutated p53.
• In patients, NR1D2 expression correlated with poorly differentiated tumors and high CSC marker expression, but only in wild-type p53 tumors.

Conclusions:

• NR1D2 regulates cancer stemness in a p53-dependent manner in colorectal cancer.
• These findings suggest NR1D2 antagonists could be a potential therapeutic strategy for specific CRC patient groups.
• Further research into the precise mechanisms is warranted for personalized medicine development.